Archive

Medical Category: Hematology and Oncology

Factor Xa Inhibitor Related ICH & PCCs

Background: Factor Xa inhibitors have gained more use over the past several years due to the ease of administration and easier monitoring. However, bleeding, namely intracranial hemorrhage (ICH) is still a risk and the lack of a proven antidote is ...

Read More
Hematology and Oncology

REBEL Cast Ep81: COVID-19, Thrombosis, and Anticoagulation

Early reports have shown that COVID-19 is most likely causing a hypercoagulable state, however the prevalence of acute VTE and exactly how to treat it is an evolving area.  Limited data suggest pulmonary microvascular thrombosis may play a role in ...

Read More
Hematology and OncologyInfectious Disease

RESTART: REstart or STop Antithrombotics Randomized Trial

Background:  In patients with ICH, antiplatelet therapy is withheld due to the perceived risk of hematoma expansion.  Often, these medications are either not restarted or there is prolonged delays until they are restarted, but the risk of occlusive vascular events ...

Read More
Hematology and Oncology

REBEL Review 90: Weight-Based Dosing of 4 Factor PCC

Read More
REBEL Reviews

REBEL Core Cast 14.0 – Superficial Venous Thrombosis

Take Home Points on SVT Superficial venous thrombosis refers to a clot and inflammation in the larger, or “axial” veins of the lower extremities and superficial thrombophlebitis refers to clot and inflammation in the tributary veins of the lower extremities. ...

Read More
Hematology and Oncology
Showing Slide 1 of 6
rebelSWAG-lightbg
gsep-logo-1

Sponsored